RT Journal Article
SR Electronic
T1 Integration of Electrochemical Sensing and Machine Learning to Detect Tuberculosis via Methyl Nicotinate in Patient Breath
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.05.23.24307746
DO 10.1101/2024.05.23.24307746
A1 Jeppson, Mary A.
A1 Rasmussen, Zachary
A1 Castro, Robert
A1 Nalugwa, Talemwa
A1 Kisakye, Esther
A1 Mangeni, Wilson
A1 Andama, Alfred
A1 Jaganath, Devan
A1 Cattamanchi, Adithya
A1 Mohanty, Swomitra K.
YR 2024
UL http://medrxiv.org/content/early/2024/06/14/2024.05.23.24307746.abstract
AB Tuberculosis (TB) remains a significant global health issue; making early, accurate, and inexpensive point-of-care detection critical for effective treatment. This paper presents a clinical demonstration of an electrochemical sensor that detects methyl-nicotinate (MN), a volatile organic biomarker associated with active pulmonary tuberculosis. The sensor was initially tested on a patient cohort comprised of 57 adults in Kampala, Uganda, of whom 42 were microbiologically confirmed TB-positive and 15 TB-negative. The sensor employed a copper(II) liquid metal salt solution with a square wave voltammetry method tailored for MN detection using commercially available screen-printed electrodes. An exploratory machine learning analysis was performed using XGBOOST. Utilizing this approach, the sensor was 78% accurate with 71% sensitivity and 100% specificity. These initial results suggest the sensing methodology is effective in identifying TB from complex breath samples, providing a promising tool for non-invasive and rapid TB detection in clinical settings.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the National Institutes of Health, National Heart, Lung and Blood Institute, under Grant R01HL139717, and the National Institutes of Allergy and Infectious Diseases, under Grant U01AI152087. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Makerere University, College of Health Science School of Medicine, IRB Approval Granted University of California-San Francisco Human Research Protection Program Institutional Review Board IRB Approval Granted IRB # 20-32670I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors